Takara Bio and Jichi Medical University Hospital announce clinical study for ex-vivo gene therapy based on chimeric antigen receptor (CAR)

The study will target the CD19 antigen-specific chimeric antigen receptor for (B-NHL) non-Hodgkin’s lymphoma. A retroviral vector MSKCC (“RetroNectin”) will be used for delivery, and results will be studied on 6 – 18 patients for 3 years.

Takara Bio news release, March 13, 2014

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny